Table 2.

Studies for SiNPs as DDS and their findings

SiNPs DDS	Targeted disease	Findings	Ref.
Radially MSN loaded with Dexamethasone	Rheumatoid arthritis	Efficient drug loading Decreased inflammation in rat models	[49]
Hyaluronic acid-functionalized MSN loaded with Simvastatin	Atherosclerosis	Reduced the secretion of proinflammatory cytokines Prolonged circulation in the blood	[50]
Leptin and Pioglitazone-loaded MSN	Amyotrophic lateral sclerosis	Prevented drug degradation Improved motor function in mice over time	[51]
5-Fluorouracil-loaded MSN	Ophthalmic drug delivery/Glaucoma	Enhanced ocular bioavailability of the drug Increased ocular retention Light irritation of the eye	[52]
MSN arctigenin/CAQK composite	Spinal cord injury	Efficient blood–spinal cord barrier crossing Improved nerve function Decreased inflammation Astrocyte’s function regulation	[53]
Gentamicin-loaded SiNPs	Skin bacterial infections	Good dispersion Controlled release Increased drug availability on the skin Antibacterial effect	[54]
L-arginine MSN	Cariogenic bacteria	Bacteria growth inhibition Prevented biofilm formation Prolonged drug release	[55]
Curcumin-loaded SiNPs	Periodontal disease	Controlled release of drug Bacteria inhibition Prevented biofilm formation	[56]
Silver/SiNPs	Fungal infections	Non-toxic Physical barrier against mycelial invasion Fungal growth inhibition	[57]

CAQK: Cysteine–alanine–lysine glutamine; DDS: Drug delivery systems; MSN: Mesoporous silica nanoparticle; SiNPs: Silica nanoparticles